Rocket Pharmaceuticals stockholders elect directors, ratify auditor, approve say-on-pay and stock option exchange

ROCKET PHARMACEUTICALS, INC.

Seven director nominees elected; David P. Southwell received 43.2M for, 20.1M withheld (lowest support).
Ratification of EisnerAmper as independent auditor: 79.2M for, 1.0M against, 0.6M abstain.
Non-binding advisory vote on executive compensation approved: 61.4M for, 1.7M against, 0.2M abstain.
Stock option exchange program approved with 45.6M for, 17.6M against (significant opposition).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

ROCKET PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-20 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-20

Exact text from the filing

The final votes were: Votes For Votes Against Abstentions Broker Non-Votes 61,389,376 1,671,016 223,752 17,490,515

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

ROCKET PHARMACEUTICALS, INC. shareholders approved Election of seven directors to the Board at the 2026-05-20 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-20

Exact text from the filing

The Company’s stockholders approved the election of seven directors to the Company’s Board of Directors (“Board”) by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Peter Fong, M.D. 62,067,824 1,216,320 17,490,515 Carsten Boess 62,711,345 572,799 17,490,515 Mikael Dolsten, M.D., Ph.D. 59,500,907 3,783,237 17,490,515 Fady Malik, M.D., Ph.D. 62,755,875 528,269 17,490,515 Gaurav Shah, M.D. 62,808,593 475,551 17,490,515 David P. Southwell 43,172,112 20,112,032 17,490,515 Roderick Wong, M.D. 62,699,331 584,813 17,490,515

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

ROCKET PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered accounting firm for fiscal year ending December 31, 2026 at the 2026-05-20 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-20

Exact text from the filing

Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes: Votes For Votes Against Abstentions 79,195,009 1,002,656 576,994

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

ROCKET PHARMACEUTICALS, INC. shareholders approved Stock option exchange program at the 2026-05-20 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-20

Exact text from the filing

Proposal Four – Stock Option Exchange Program The Company’s stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement. The final votes were: Votes For Votes Against Abstentions Broker Non-Votes 45,582,445 17,615,213 86,486 17,490,515

View on SEC.gov

Browse all shareholder votes →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-022311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.